Clinical Trial Update: mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of modified DCF chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) with Avelumab in resectable esophago-gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Avelumab (avelumab)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Status: UNKNOWN